Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | OXTR | P30559 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31351894 | 1.00 | HDAC1 (0.54) | HDAC1KDM4EMAPTMAPK1OXTR | |
| SCHEMBL675283 | 0.75 | KDM4E (0.50) | KDM4EMAPTMEN1KMT2AHPGD | |
| SCHEMBL29523322 | 0.73 | NPC1 (0.59) | KDM4EMAPTAPPHDAC6CLK4 | |
| SCHEMBL21682139 | 0.73 | NPC1 (0.59) | KDM4EMAPTAPPHDAC6CLK4 | |
| SCHEMBL17433883 | 0.72 | APP (0.54) | MAPTAPPCLK4NCF1EGFR | |
| SCHEMBL412384 | 0.72 | CLK4 (0.52) | MAPTCLK4MEN1KMT2AHPGD | |
| SCHEMBL677303 | 0.71 | UTS2R (0.51) | KDM4EMAPTMEN1KMT2ANPC1 | |
| SCHEMBL28805360 | 0.71 | RAB9A (0.72) | HDAC1KDM4EMAPTMAPK1APP | |
| SCHEMBL24506778 | 0.71 | KDM4E (0.63) | KDM4EMAPTMAPK1OXTRCNR1 | |
| SCHEMBL30589325 | 0.71 | APP (0.52) | MAPTAPPCLK4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3817748-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | CRBN, CRKL, CUL4A | HDAC1 1172/4885KDM4E 2339/4885MAPT 1069/4885 |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | CRBN, CRKL, CUL4A | HDAC1 1172/4885KDM4E 2339/4885MAPT 1069/4885 |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | HDAC1 1172/4885KDM4E 2339/4885MAPT 1069/4885 |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | HDAC1 1172/4885KDM4E 2339/4885MAPT 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.